Firemaster Bp-6

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:209990	IVR	5 mg/kg/day	5 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	5 mg/kg/day	5 mg/kg/day	Alterations in vaginal opening	Reproductive endocrine-mediated perturbations
	IVR	0.5 mg/kg/day	-	No significant effects observed	-
	IVR	0.25 mg/kg/day	-	No significant effects observed	-
	IVR	10 mg/kg/day	10 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Alterations in vaginal opening	Reproductive endocrine-mediated perturbations
	IVR	1 mg/kg/day	1 mg/kg/day	Alterations in vaginal opening	Reproductive endocrine-mediated perturbations
	IVR	1 mg/kg/day	1 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
PMID:6302948	IVR	3 mg/kg/day	3 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	3 mg/kg/day	3 mg/kg/day	Affects the biochemical composition of liver	Hepatic endocrine-mediated perturbations
	IVR	3 mg/kg/day	3 mg/kg/day	Decreased thymus gland weights	Immunological endocrine-mediated perturbations
	IVR	3 mg/kg/day	3 mg/kg/day	Decrease in T3 levels	Metabolic endocrine-mediated perturbations
	IVR	3 mg/kg/day	3 mg/kg/day	Decrease in T4 levels	Metabolic endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Decrease in T3 levels	Metabolic endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Affects the biochemical composition of liver	Hepatic endocrine-mediated perturbations
	IVR	0.1 mg/kg/day	-	No significant effects observed	-
	IVR	10 mg/kg/day	10 mg/kg/day	Decrease in T4 levels	Metabolic endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Decreased thymus gland weights	Immunological endocrine-mediated perturbations
	IVR	1 mg/kg/day	1 mg/kg/day	Decreased thymus gland weights	Immunological endocrine-mediated perturbations
	IVR	1 mg/kg/day	1 mg/kg/day	Affects the biochemical composition of liver	Hepatic endocrine-mediated perturbations
	IVR	1 mg/kg/day	1 mg/kg/day	Decrease in T4 levels	Metabolic endocrine-mediated perturbations
	IVR	1 mg/kg/day	1 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	1 mg/kg/day	1 mg/kg/day	Decrease in T3 levels	Metabolic endocrine-mediated perturbations
	IVR	0.3 mg/kg/day	0.3 mg/kg/day	Decrease in T4 levels	Metabolic endocrine-mediated perturbations
	IVR	0.3 mg/kg/day	0.3 mg/kg/day	Affects the biochemical composition of liver	Hepatic endocrine-mediated perturbations
	IVR	0.3 mg/kg/day	0.3 mg/kg/day	Decreased thymus gland weights	Immunological endocrine-mediated perturbations
	IVR	0.3 mg/kg/day	0.3 mg/kg/day	Decrease in T3 levels	Metabolic endocrine-mediated perturbations
	IVR	0.3 mg/kg/day	0.3 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.